Literature DB >> 8631805

Activated neu induces rapid tumor progression.

C T Guy1, R D Cardiff, W J Muller.   

Abstract

Expression of the activated neu oncogene in transgenic mice has been associated with both the synchronous (single-step) and the stochastic (multistep) transformation of the mammary epithelium. To determine the basis for these conflicting observations, additional strains of transgenic mice carrying the activated neu oncogene under the transcriptional control of the mouse mammary tumor virus promoter/enhancer were produced. Activated neu transgene expression, as measured by in situ hybridization and ribonuclease protection assays, resulted in rapid conversion of the normal mammary epithelium to malignant phenotype in three independent strains of mice. Expression of the transgene in male mice led to epithelial hyperplasia of the epididymis and male infertility but not malignancy. These results indicate that tissue context is an important parameter in malignant progression and that expression of appropriate levels of activated neu is sufficient for rapid production of mammary tumors in transgenic mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8631805     DOI: 10.1074/jbc.271.13.7673

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 2.  Interrogating mouse mammary cancer models: insights from gene expression profiling.

Authors:  Antonio A Fargiano; Kartiki V Desai; Jeffrey E Green
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

3.  The normal mammary microenvironment suppresses the tumorigenic phenotype of mouse mammary tumor virus-neu-transformed mammary tumor cells.

Authors:  B W Booth; C A Boulanger; L H Anderson; G H Smith
Journal:  Oncogene       Date:  2010-10-04       Impact factor: 9.867

4.  Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.

Authors:  D Dankort; B Maslikowski; N Warner; N Kanno; H Kim; Z Wang; M F Moran; R G Oshima; R D Cardiff; W J Muller
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

5.  Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.

Authors:  R J Lee; C Albanese; M Fu; M D'Amico; B Lin; G Watanabe; G K Haines; P M Siegel; M C Hung; Y Yarden; J M Horowitz; W J Muller; R G Pestell
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

6.  Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.

Authors:  P M Siegel; E D Ryan; R D Cardiff; W J Muller
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

Review 7.  The comparative pathology of human and mouse mammary glands.

Authors:  R D Cardiff; S R Wellings
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

Review 8.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 9.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

10.  Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis.

Authors:  Eran R Andrechek; William R Hardy; Michael A Laing; William J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.